Skip to main content

Peer Review reports

From: Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

Original Submission
12 Oct 2021 Submitted Original manuscript
31 Oct 2021 Reviewed Reviewer Report
4 Nov 2021 Reviewed Reviewer Report
7 Dec 2021 Author responded Author comments - Zhengbo Song
Resubmission - Version 2
7 Dec 2021 Submitted Manuscript version 2
8 Dec 2021 Reviewed Reviewer Report
22 Dec 2021 Reviewed Reviewer Report
29 Dec 2021 Author responded Author comments - Zhengbo Song
Resubmission - Version 3
29 Dec 2021 Submitted Manuscript version 3
7 Jan 2022 Author responded Author comments - Zhengbo Song
Resubmission - Version 4
7 Jan 2022 Submitted Manuscript version 4
Publishing
10 Jan 2022 Editorially accepted
1 Feb 2022 Article published 10.1186/s12916-022-02245-z

You can find further information about peer review here.

Back to article page